Alfred S Barritt

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4406808/publications.pdf

Version: 2024-02-01

93 papers 5,953 citations

147801 31 h-index 76900 74 g-index

94 all docs 94 docs citations

times ranked

94

8389 citing authors

#	Article	IF	CITATIONS
1	Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2018. Gastroenterology, 2019, 156, 254-272.e11.	1.3	1,040
2	Burden of Gastrointestinal, Liver, and Pancreatic Diseases in the United States. Gastroenterology, 2015, 149, 1731-1741.e3.	1.3	793
3	Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study. Journal of Hepatology, 2021, 74, 567-577.	3.7	377
4	A Histologic Scoring System for Prognosis of Patients With AlcoholicÂHepatitis. Gastroenterology, 2014, 146, 1231-1239.e6.	1.3	353
5	NAFLD and liver transplantation: Current burden and expected challenges. Journal of Hepatology, 2016, 65, 1245-1257.	3.7	352
6	COVID-19 and liver disease: mechanistic and clinical perspectives. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 348-364.	17.8	272
7	Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis. Digestive Diseases and Sciences, 2015, 60, 3318-3328.	2.3	251
8	High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary resultsÂfrom an international registry. Journal of Hepatology, 2020, 73, 705-708.	3.7	213
9	Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study. The Lancet Gastroenterology and Hepatology, 2020, 5, 1008-1016.	8.1	194
10	Declining liver utilization for transplantation in the United States and the impact of donation after cardiac death. Liver Transplantation, 2013, 19, 59-68.	2.4	120
11	Decreasing Mortality Among Patients Hospitalized With Cirrhosis in the United States From 2002 Through 2010. Gastroenterology, 2015, 148, 967-977.e2.	1.3	116
12	Declining liver graft quality threatens the future of liver transplantation in the United States. Liver Transplantation, 2015, 21, 1040-1050.	2.4	97
13	Characteristics of Adults in the Hepatitis B Research Network in North America Reflect Their Country of Origin and Hepatitis B Virus Genotype. Clinical Gastroenterology and Hepatology, 2015, 13, 183-192.	4.4	90
14	Determining risk factors for mortality in liver transplant patients with COVID-19. The Lancet Gastroenterology and Hepatology, 2020, 5, 643-644.	8.1	90
15	SARS-CoV-2 infection in patients with autoimmune hepatitis. Journal of Hepatology, 2021, 74, 1335-1343.	3.7	90
16	Alcohol-Related Liver Disease Is Rarely Detected at Early Stages Compared With Liver Diseases of Other Etiologies Worldwide. Clinical Gastroenterology and Hepatology, 2019, 17, 2320-2329.e12.	4.4	87
17	Paracentesis Is Associated With Reduced Mortality in Patients Hospitalized With Cirrhosis and Ascites. Clinical Gastroenterology and Hepatology, 2014, 12, 496-503.e1.	4.4	77
18	Intestinal microbiota in liver disease. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2016, 30, 133-142.	2.4	65

#	Article	IF	CITATIONS
19	Changing shape of disease: Nonalcoholic fatty liver disease in CrohnÊ⅓s diseaseâ€"A case series and review of the literature. Inflammatory Bowel Diseases, 2012, 18, 49-54.	1.9	57
20	The Influence of Nonalcoholic Fatty Liver Disease and Its Associated Comorbidities on Liver Transplant Outcomes. Journal of Clinical Gastroenterology, 2011, 45, 372-378.	2.2	54
21	Maximizing Opportunities and Avoiding Mistakes in Triple Therapy for Hepatitis C Virus. Gastroenterology, 2012, 142, 1314-1323.e1.	1.3	50
22	Periodontitis and Nonâ€alcoholic Fatty Liver Disease, a populationâ€based cohort investigation in the Study of Health in Pomerania. Journal of Clinical Periodontology, 2017, 44, 1077-1087.	4.9	49
23	SARS-CoV-2 vaccination in patients with liver disease: responding to the next big question. The Lancet Gastroenterology and Hepatology, 2021, 6, 156-158.	8.1	49
24	Diabetes Is Associated with Clinical Decompensation Events in Patients with Cirrhosis. Digestive Diseases and Sciences, 2016, 61, 3335-3345.	2.3	48
25	Rising Mortality From Alcohol-Associated Liver Disease in the United States in the 21st Century. American Journal of Gastroenterology, 2020, 115, 79-87.	0.4	47
26	Transporterâ€Mediated Alterations in Patients With NASH Increase Systemic and Hepatic Exposure to an OATP and MRP2 Substrate. Clinical Pharmacology and Therapeutics, 2018, 104, 749-756.	4.7	41
27	Increasing Prevalence of Hepatitis C among Hospitalized Children Is Associated with an Increase in Substance Abuse. Journal of Pediatrics, 2018, 192, 159-164.	1.8	38
28	Alcohol-Associated Liver Disease Mortality Increased From 2017 to 2020 and Accelerated During the COVID-19 Pandemic. Clinical Gastroenterology and Hepatology, 2022, 20, 2142-2144.e2.	4.4	38
29	Impact of nighttime and weekend liver transplants on graft and patient outcomes. Liver Transplantation, 2012, 18, 558-565.	2.4	36
30	Disparities between research attention and burden in liver diseases: implications on uneven advances in pharmacological therapies in Europe and the USA. BMJ Open, 2017, 7, e013620.	1.9	36
31	Charges for Alcoholic Cirrhosis Exceed All Other Etiologies of Cirrhosis Combined: A National and State Inpatient Survey Analysis. Digestive Diseases and Sciences, 2019, 64, 1460-1469.	2.3	36
32	SARSâ€CoVâ€2 Infections Among Patients With Liver Disease and Liver Transplantation Who Received COVIDâ€19 Vaccination. Hepatology Communications, 2022, 6, 889-897.	4.3	36
33	Colder Weather and Fewer Sunlight Hours Increase Alcohol Consumption and Alcoholic Cirrhosis Worldwide. Hepatology, 2019, 69, 1916-1930.	7.3	34
34	Time to Rethink Antiviral Treatment for Hepatitis C in Patients with Coexisting Mental Health/Substance Abuse Issues. Digestive Diseases and Sciences, 2012, 57, 1469-1474.	2.3	33
35	Local access to subspecialty care influences the chance of receiving a liver transplant. Liver Transplantation, 2013, 19, 377-382.	2.4	30
36	Marijuana Consumption in Liver Transplant Recipients. Liver Transplantation, 2019, 25, 734-740.	2.4	30

3

#	Article	IF	CITATIONS
37	Opioid prescriptions are associated with hepatic encephalopathy in a national cohort of patients with compensated cirrhosis. Alimentary Pharmacology and Therapeutics, 2020, 51, 652-660.	3.7	30
38	Elevated Liver Enzymes in Patients with COVID-19: Look, but Not Too Hard. Digestive Diseases and Sciences, 2021, 66, 1767-1769.	2.3	28
39	The impact of postâ€transplant diabetes mellitus on liver transplant outcomes. Clinical Transplantation, 2019, 33, e13554.	1.6	24
40	Characterization of the Cytochrome P450 epoxyeicosanoid pathway in non-alcoholic steatohepatitis. Prostaglandins and Other Lipid Mediators, 2016, 125, 19-29.	1.9	22
41	Low Liver Enzymes and Risk of Dementia: The Atherosclerosis Risk in Communities (ARIC) Study. Journal of Alzheimer's Disease, 2021, 79, 1775-1784.	2.6	21
42	Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGETâ€NASH Study. Hepatology Communications, 2021, 5, 938-946.	4.3	21
43	Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study. Clinical Gastroenterology and Hepatology, 2022, 20, 458-460.e4.	4.4	21
44	Periodontitis and prevalence of elevated aminotransferases in the Hispanic Community Health Study/Study of Latinos. Journal of Periodontology, 2018, 89, 949-958.	3.4	19
45	Randomized Controlled Trial of a Leucineâ€Metforminâ€Sildenafil Combination (NSâ€0200) on Weight and Metabolic Parameters. Obesity, 2019, 27, 59-67.	3.0	18
46	Detective Work in Drug-Induced Liver Injury: Sometimes It Is All About Interviewing the Right Witness. Clinical Gastroenterology and Hepatology, 2010, 8, 635-637.	4.4	17
47	Review article: role of glucagonâ€like peptideâ€l receptor agonists in nonâ€alcoholic steatohepatitis, obesity and diabetes—what hepatologists need to know. Alimentary Pharmacology and Therapeutics, 2022, 55, 944-959.	3.7	17
48	Persistent Portosystemic Shunts After Liver Transplantation Causing Episodic Hepatic Encephalopathy. Digestive Diseases and Sciences, 2010, 55, 1794-1798.	2.3	16
49	Therapy for Nonalcoholic Fatty Liver Disease: Current Options and Future Directions. Clinical Therapeutics, 2021, 43, 500-517.	2.5	16
50	Age and comorbidity are central to the risk of death from COVID-19 in liver transplant recipients. Journal of Hepatology, 2021, 75, 226-228.	3.7	16
51	Treatment of Hepatitis C during Pregnancy-Weighing the Risks and Benefits in Contrast to HIV. Current HIV/AIDS Reports, 2018, 15, 155-161.	3.1	15
52	Complications Associated With Anesthesia Services in Endoscopic Procedures Among Patients With Cirrhosis. Hepatology, 2020, 72, 2109-2118.	7.3	15
53	Serum Ammonia in Cirrhosis: Clinical Impact of Hyperammonemia, Utility of Testing, and National Testing Trends. Clinical Therapeutics, 2022, 44, e45-e57.	2.5	15
54	Tangible Resources for Preparing Patients for Antiviral Therapy for Chronic Hepatitis C. Digestive Diseases and Sciences, 2012, 57, 1439-1444.	2.3	14

#	Article	IF	CITATIONS
55	Nutrition as Therapy in Liver Disease. Clinical Therapeutics, 2022, 44, 682-696.	2.5	13
56	Oral budesonide for the therapy of post-liver transplant de novo inflammatory bowel disease: A case series and systematic review of the literature. Inflammatory Bowel Diseases, 2008, 14, 1695-1700.	1.9	12
57	Should patients with Barrett's oesophagus be kept under surveillance? The case against. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2008, 22, 741-750.	2.4	12
58	Membranoproliferative Glomerulonephritis, Type II Cryoglobulinemia and Triple Therapy for Hepatitis C: A Case Series and Review of the Literature. Digestive Diseases and Sciences, 2014, 59, 2007-2012.	2.3	12
59	What Survivorship Means to Liver Transplant Recipients: Qualitative Groundwork for a Survivorship Conceptual Model. Liver Transplantation, 2021, 27, 1454-1467.	2.4	12
60	What Liver Transplant Recipients Want in a Smartphone Intervention to Enhance Recovery: Prototype for the LiveRight Transplant App. Liver Transplantation, 2021, 27, 584-589.	2.4	11
61	Opioid Use Is More Common in Nonalcoholic Fatty Liver Disease Patients with Cirrhosis, Higher BMI, and Psychiatric Disease. Digestive Diseases, 2021, 39, 247-257.	1.9	11
62	Early Survivorship After Liver Transplantation: A Qualitative Study Identifying Challenges in Recovery From the Patient and Caregiver Perspective. Liver Transplantation, 2022, 28, 422-436.	2.4	11
63	Effect of ERCP Utilization and Biliary Complications on Post-Liver-Transplantation Mortality and Graft Survival. Digestive Diseases and Sciences, 2010, 55, 3602-3609.	2.3	10
64	In inpatients with cirrhosis opioid use is common and associated with length of stay and persistent use post-discharge. PLoS ONE, 2020, 15, e0229497.	2.5	10
65	Liver biopsy in the real world—reporting, expert concordance and correlation with a pragmatic clinical diagnosis. Alimentary Pharmacology and Therapeutics, 2021, 54, 1472-1480.	3.7	10
66	Liver transplantation in 2013: challenges and controversies. Minerva Gastroenterologica E Dietologica, 2013, 59, 117-31.	2.2	10
67	Predicting Liver Transplant Capacity Using Discrete Event Simulation. Medical Decision Making, 2015, 35, 784-796.	2.4	8
68	Who Treats Patients with Diabetes and Compensated Cirrhosis. PLoS ONE, 2016, 11, e0165574.	2.5	8
69	Immunosuppression in Autoimmune Hepatitis: Is There an End Game?. American Journal of Gastroenterology, 2020, 115, 498-501.	0.4	5
70	SARSâ€CoVâ€⊋ in Pediatric Liver Transplant Recipients. Journal of Pediatric Gastroenterology and Nutrition, 2022, 74, .	1.8	5
71	Focal Fat Masquerading as Malignancy in the Liver Graft of a Post-Transplant Patient. Digestive Diseases and Sciences, 2011, 56, 3382-3385.	2.3	4
72	A 52-Year-Old Man With Heartburn: Should He Undergo Screening for Barrett's Esophagus?. Clinical Gastroenterology and Hepatology, 2010, 8, 565-571.	4.4	3

#	Article	IF	Citations
73	Single-balloon enteroscopy-assisted endoscopic retrograde cholangiopancreatography for treatment of cholangitis in a patient with a Kasai portoenterostomy. Journal of Pediatric Surgery, 2012, 47, e1-e5.	1.6	3
74	Newer second-line glucose-lowering drugs versus thiazolidinediones on cirrhosis risk among older US adult patients with type 2 diabetes. Journal of Diabetes and Its Complications, 2020, 34, 107706.	2.3	3
75	Antiplatelet Medications Are Associated With Bleeding and Decompensation Events Among Patients With Cirrhosis. Journal of Clinical Gastroenterology, 2022, 56, 627-634.	2.2	3
76	Letter to the Editor: Proton Pump Inhibitors in Cirrhosis: A Marker of Morbid Conditions or a Cause of Mortality?. Hepatology, 2019, 70, 761-762.	7.3	2
77	A Quality Improvement Initiative Results in Improved Rates of Timely Postvariceal Bleeding Surveillance Endoscopy. American Journal of Gastroenterology, 2020, 115, 625-628.	0.4	2
78	Nonalcoholic Fatty Liver Disease: Epidemiology, Assessments, and Interventions Entering 2021. Clinical Therapeutics, 2021, 43, 436-437.	2.5	2
79	OTH-1â€SARS-CoV-2 Infection in patients with autoimmune hepatitis. , 2021, , .		2
80	S1858 The Influence of NAFLD and Its Associated Comorbidities on Liver Transplant Outcomes. Gastroenterology, 2010, 138, S-804.	1.3	1
81	COVID-19 and liver transplantation: the jury is still out $\hat{a} \in \text{``Authors''}$ reply. The Lancet Gastroenterology and Hepatology, 2021, 6, 11.	8.1	1
82	Periodontitis is associated with increased liver fibrosis in a populationâ€based cohort of US adults. GastroHep, 2021, 3, 179-184.	0.6	1
83	O07â€FXR antagonists as new agents for COVID19. , 2021, , .		1
84	PO48â€Geographic variability in rates of intensive care unit admission in patients with chronic liver disease and critical COVID-19: International registry data., 2021,,.		1
85	New and Evolving Management Paradigms for Hepatitis C after Liver Transplantation. Current Hepatitis Reports, 2011, 10, 179-185.	0.3	0
86	Impact of Physician Specialty Mix on the Outcomes of Patients Dually Diagnosed With Diabetes and Compensated Cirrhosis. Diabetes Care, 2017, 40, e137-e138.	8.6	0
87	Letter: are opioid prescriptions associated with hepatic encephalopathy in patients with compensated cirrhosis? Authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 51, 743-744.	3.7	0
88	Dynamic α-Fetoprotein Response—Are We Ready to Change the Dynamics of Hepatocellular Carcinoma Liver Transplant Practice?. JAMA Surgery, 2021, 156, 567.	4.3	0
89	REPLY:. Hepatology, 2021, 74, 2315-2316.	7.3	0
90	How Potential Living Donors Improve Patient Survival in Hepatocellular Carcinomaâ€"A Liver for a Life. JAMA Surgery, 2021, 156, e213123.	4.3	0

ALFRED S BARRITT

#	Article	IF	CITATIONS
91	Management of anemia in patients receiving triple therapy for hepatitis C. Gastroenterology and Hepatology, 2013, 9, 314-6.	0.1	O
92	Editorial: targeting liver biopsy in NAFLD—the need to expand our nonâ€invasive tools. Authors' reply. Alimentary Pharmacology and Therapeutics, 2022, 55, 128-128.	3.7	0
93	We Are What We Eat: Food as Medicine in Health and Disease. Clinical Therapeutics, 2022, , .	2.5	O